Header graphic for print
The Healthcare Investor Insights on Issues & Trends that Impact Investments in Healthcare & Life Science Businesses

Healthcare & Life Sciences Private Equity Deal Tracker: Precision BioSciences Secures $25.6 Million in Financing

Posted in Life Sciences Investing

Precision BioSciences has announced it has secured $25.6 million in series A financing.

Precision BioSciences is a Durham, N.C.-based genome editing company. Its ARCUS genome editing technology is designed to produce nucleases that can insert, remove and modify DNA in a complex genome.

The funding round involved Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund and two public market investors.

As Precision’s CEO Matthew Kane indicated in a news release, “This financing will allow us to expand beyond our successful efforts to develop the leading next-gen genome editing platform and significantly accelerate the development of our genome-edited product pipeline.”

We use cookies to enhance your experience of our website. By continuing to use this website, you agree to the use of these cookies. For more information and to learn how you can change your cookie settings, please see our policy.

Agree